Search Result
Results for "
A2 Inhibitors
" in MedChemExpress (MCE) Product Catalog:
4
Biochemical Assay Reagents
3
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-108607
-
Palmityltrifluoromethylketone
|
Phospholipase
|
Inflammation/Immunology
|
PACOCF3 (Palmityltrifluoromethylketone) is a selective phospholipase A2 inhibitor with an IC50 of 3.8 μM. PACOCF3 alters Ca 2+ signaling in renal tubular cells .
|
-
-
- HY-P3884
-
|
Bacterial
Antibiotic
|
Infection
|
Arylomycin A2, an antibiotic (Antibiotic), is a lipopeptide type I signal peptidase (SPase I) inhibitor. Arylomycin A2 has antibacterial effects .
|
-
-
- HY-111532B
-
|
ClpP
|
Infection
|
(3S,4S)-A2-32-01 (compound 24(S,S)), a less active (S,S)-enantiomer of A2-32-01. A2-32-01 is a potent caseinolytic protein proteases (ClpP) inhibitor .
|
-
-
- HY-W396889
-
-
-
- HY-N8041
-
|
HSV
|
Infection
|
Mogroside III A2 is a cucurbitane glycoside. Mogroside III A2 can inhibit Epstein-Barr virus early antigen (EBV-EA) activation. Mogroside III A2 shows weak inhibitory effects on activation of NOR 1 .
|
-
-
- HY-19189
-
-
-
- HY-N7614
-
Schidigerasaponin F2; Timosaponin AII
|
Others
|
Cardiovascular Disease
|
Anemarrhenasaponin A2 (Schidigerasaponin F2) is a steroidal saponin isolated from the rhizomes of Anemarrhena asphodeloides. Anemarrhenasaponin A2 inhibits ADP-induced platelet aggregation .
|
-
-
- HY-N10502
-
|
MDM-2/p53
HSP
|
Cancer
|
Colletofragarone A2 can be be isolated from the fungus Colletotrichum sp. (13S020). Colletofragarone A2 inhibits mutant p53 and HSP90 with anti-cancer activity. Colletofragarone A2 promotes degradation and aggregation of mutant p53 and suppressing tumor growth in vivo .
|
-
-
- HY-P10053
-
|
Phospholipase
|
Metabolic Disease
|
sPLA2-IIA Inhibitor is a cyclic pentapeptide analog of FLSYK (cyclic 2-Nal-Leu-Ser-2-Nal-Arg (c2)), that binds to hGIIA (human IIA phospholipase A2) and inhibits its hydrolytic ability. sPLA2 is a member of the esterase superfamily that catalyzes the hydrolysis of the ester bond at the sn-2 position of glycerophospholipids, releasing free fatty acids such as arachidonic acid and lysophospholipids .
|
-
-
- HY-130337
-
|
Antibiotic
Bacterial
|
Infection
|
Teicoplanin A2-2 is a glycopeptide antibiotic. Teicoplanin A2-2 exhibits antibacterial activity, particularly against coagulase-negative staphylococci (CNS). Teicoplanin A2-2 inhibits bacterial cell wall synthesis by competitively binding to the terminal D-Ala-D-Ala peptide bonds in the cell wall synthesis process, leading to bacterial death. Teicoplanin A2-2 can be used for research into bacterial resistance mechanisms and the development of new antibiotics .
|
-
-
- HY-115062
-
|
Phospholipase
|
Metabolic Disease
|
MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6 .
|
-
-
- HY-116281
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
ICI D1542 is a selective and potent inhibitor of thromboxane A2 (TXA2) synthase and the thromboxane A2 receptor (TP-receptor). ICI D1542 is effective at preventing thrombus formation by redirection of arachidonic acid metabolism .
|
-
-
- HY-A0221
-
R 68070
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities .
|
-
-
- HY-124150
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
BM567 is a sulfonylurea compound (compound 1), which exhibits antithrombogenic efficacy as thromboxane A2 receptor (TXR) antagonists and thromboxane A2 synthase (TXS) inhibitors, with IC50s of 1.1 and 12 nM, respectively .
|
-
-
- HY-111532
-
|
ClpP
Bacterial
|
Infection
|
(3R,4R)-A2-32-01 (compound 24(R,R)), the (R,R)-enantiomer of A2-32-01, is a Staphylococcus aureus caseinolytic protease (SaClpP) inhibitor .
|
-
-
- HY-P10785
-
|
Bacterial
Antibiotic
|
Infection
|
Iturin A-2 is a cyclic lipopeptide discovered in B. subtilis and exhibits inhibitory activity against the plant pathogenic fungus P. expansum (MIC = 8 µg/disk). Iturin A-2 is cytotoxic to MCF-7 and BT474 breast cancer cells, as well as HeLa cervical cancer cells, with IC50 values of 66.81, 95.04, and 77.5 µg/mL, respectively. In greenhouse studies, Iturin A-2 at concentrations of 100 and 300 mg/kg Iturin A-2 reduces the lesion area of southern corn leaf blight caused by B. maydis, and in field studies, concentrations of 300 and 500 mg/kg Iturin A-2 reduce the incidence of the disease. Iturin A-2 (12.5 µg/mL) inhibits cell division, but not nuclear division, in isolated fertilized starfish eggs .
|
-
-
- HY-101606
-
-
-
- HY-158332
-
SKF-95587; BM-13177
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Sulotroban (SKF-95587; BM-13177) is a selective antagonist for thromboxane A2 receptor (TXA2 Receptor). Sulotroban exhibits inhibitory activity against carbocyclic thromboxane A2- and endoperoxide-induced vasoconstrictor. Sulotroban inhibits platelets aggregation .
|
-
-
- HY-101195
-
|
PKC
Phospholipase
|
Cancer
|
DL-erythro-Dihydrosphingosine is a potent inhibitor of PKC and phospholipase A2 (PLA2) .
|
-
-
- HY-125157
-
-
-
- HY-115855
-
-
-
- HY-108132
-
-
-
- HY-129944
-
|
Phospholipase
|
Inflammation/Immunology
|
MJ33-OH is a metabolite of MJ33. MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6 .
|
-
-
- HY-129944A
-
|
Phospholipase
|
Inflammation/Immunology
|
MJ33-OH lithium is a metabolite of MJ33. MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6 .
|
-
-
- HY-138001
-
-
-
- HY-19920
-
-
-
- HY-100257
-
-
-
- HY-113560
-
-
-
- HY-110390
-
-
-
- HY-N7036
-
|
Phospholipase
|
Inflammation/Immunology
|
Rhamnetin is a quercetin derivative found in Coriandrum sativum, inhibits secretory phospholipase A2, with antioxidant and anti-inflammatory activity .
|
-
-
- HY-W100403
-
Choline p-toluenesulfonate
|
Phospholipase
|
Cancer
|
Choline tosylate is a nucleophilic compound that inhibits phospholipase A2 and phospholipase C. Choline tosylate inhibits tumor growth in mice by inhibiting the formation of diacylglycerol (DAG) .
|
-
-
- HY-17448
-
-
-
- HY-116671
-
|
Phospholipase
|
Others
|
Folipastatin is a potent inhibitor of phospholipase A2 with an IC50 of 39 μM. Folipastatin is a new depsidone compound from Aspergillus unguis .
|
-
-
- HY-100261
-
-
-
- HY-146646
-
|
Antibiotic
|
Infection
Cancer
|
Bleomycin A2, an antitumor antibiotic promoting DNA-degradation, is an aspartate/asparagine-β-hydroxylase (AspH) inhibitor with an IC50 of 1.47 μM .
|
-
-
- HY-120441
-
-
-
- HY-N0604
-
-
-
- HY-N1450
-
|
Phospholipase
|
Cancer
|
Aristolochic acid C is a derivative of Aristolochic acid. Aristolochic acid is a phospholipase A2 (PLA2) inhibitor, which disrupts cortical microtubule arrays and root growth in Arabidopsis .
|
-
-
- HY-18744
-
|
FLT3
|
Cancer
|
FLT3-IN-2 is a FLT3 inhibitor with IC50 of < 1 μM, detailed information refer to WO 2012158957 A2 and WO 2007013896.
|
-
-
- HY-13277
-
|
IRAK
|
Inflammation/Immunology
|
IRAK inhibitor 3 is an interleukin-1 (IL-I) receptor-associated kinase (IRAK) kinase modulator extracted from patent WO2008030579 A2.
|
-
-
- HY-14952
-
PLA-695
|
Phospholipase
|
Inflammation/Immunology
Cancer
|
Giripladib (PLA-695) is a indole-based inhibitor of cytosolic phospholipase A2 (cPLA2). Giripladib can be used for osteoarthritis and breast cancer research .
|
-
-
- HY-U00308
-
-
-
- HY-W273690
-
1-Hexyltheobromine; Hexyltheobromine
|
Others
|
Cardiovascular Disease
|
Pentifylline is a vasodilator. Pentifylline inhibits platelet aggregation and thromboxane A2 synthesis, decrease the release of free radicals. Pentifylline has the potential for the research of acute ischaemic stroke .
|
-
-
- HY-N8610
-
|
Phosphatase
|
Inflammation/Immunology
|
Uralsaponin D is a saponin that can be isolated from Glycyrrhiza inflata. Uralsaponin D inhibits phospholipase A2 (PLA2) with an IC50 value of 32.2 μM .
|
-
-
- HY-B0428A
-
OKY-046 sodium
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM .
|
-
-
- HY-B0428B
-
OKY-046 hydrochloride
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC50 of 53.12 μM .
|
-
-
- HY-106066
-
UK38485
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Dazmegrel (UK-38485) is a thromboxane synthetase inhibitor which inhibits Thromboxane A2 (TXA2) synthesis and exhibits antiplatelet vasodilator effects. Dazmegrel can be utilized in thrombosis research .
|
-
-
- HY-W012595A
-
trans-Benzalacetone
|
Phospholipase
|
Inflammation/Immunology
|
trans-Benzylideneacetone (trans-Benzalacetone), a metabolite of gram-negative entomopathogenic bacterium Xenorhabdus nematophila, is an enzyme inhibitor against phospholipase A2 (PLA2). trans-Benzylideneacetone is an immunosuppressant .
|
-
-
- HY-112738
-
|
Phospholipase
|
Inflammation/Immunology
|
AX048 is an inhibitor for calcium-dependent phospholipase A2 cPLA2 with a XI(50) of 0.022 mole fraction and reveals an antihyperalgesic efficacy .
|
-
-
- HY-P10447
-
Fengycin IX; SNA-60-367-3
|
Phospholipase
|
Inflammation/Immunology
|
Plipastatin A1 is a lipopeptide with enzyme inhibitory and immunosuppressive activities. Plipastatin A1 is found in Bacillus cereus and inhibits phospholipase A2 (PLA2), PLC, and PLD .
|
-
- HY-101692
-
-
- HY-106555
-
|
Phospholipase
|
Inflammation/Immunology
|
Protizinic acid is an orally active non-steroidal antiinflammatory agent with antiinflammatory and antipyretic activity. Protizinic acid inhibits phospholipase A2 (PLA2) activity, and the IC50 value is 210 μM .
|
-
- HY-116560
-
-
- HY-119890
-
-
- HY-18763
-
Ibustrin
|
COX
|
Cardiovascular Disease
|
Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .
|
-
- HY-18763A
-
Ibustrin sodium
|
COX
|
Cardiovascular Disease
|
Indobufen sodium is a platelet aggregation inhibitor. Indobufen sodium is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen sodium suppresses thromboxane A2 (TxA2) synthesis. Indobufen sodium down-regulates tissue factor (TF) in monocytes .
|
-
- HY-B0745
-
-
- HY-125637
-
Aabomycin A2
|
Antibiotic
Fungal
ATP Synthase
|
Infection
|
Venturicidin B (Aabomycin A2) is a macrolide antibiotic isolated from Streptomyces sp., used as an antifungal agent, a potent inhibitor of the mitochondrial F0-ATP synthase complex .
|
-
- HY-153561A
-
|
Phospholipase
|
Neurological Disease
|
Lp-PLA2-IN-16 (example 1) is a lipoprotein-associated phospholipase A2 (Lp-PLA 2) inhibitor, which can be used in the research of Alzheimer's disease, etc .
|
-
- HY-153561
-
|
Phospholipase
|
Neurological Disease
|
Lp-PLA2-IN-15 (example 2) is a lipoprotein-associated phospholipase A2 (Lp-PLA 2) inhibitor, which can be used in the research of Alzheimer's disease, etc .
|
-
- HY-145384
-
|
Phospholipase
|
Inflammation/Immunology
|
ROC-0929 (compound 13a) is a potent and selective inhibitor of secreted phospholipases A2 (sPLA2s) with an IC50 of 80 nM, specially targeting hGX. ROC-0929 inhibits the phosphorylation of ERK1/2 and p-38. Secreted phospholipases A2 (sPLA2s) are a family of disulfide-rich, Ca 2+-dependent enzymes that hydrolyze the sn-2 position of glycero-phospholipids to release a fatty acid and a lysophospholipid. ROC-0929 has the potential for researching inflammation related diseases .
|
-
- HY-100083
-
|
HIV
|
Others
|
Dolutegravir intermediate-1 is a synthetic intermediate of Dolutegravir extracted from patent WO 2016125192 A2. Dolutegravir is an integrase inhibitor developed for the treatment of human immunodeficiency virus (HIV)-1 infection.
|
-
- HY-101015A
-
-
- HY-N7036R
-
|
Phospholipase
|
Inflammation/Immunology
|
Rhamnetin (Standard) is the analytical standard of Rhamnetin. This product is intended for research and analytical applications. Rhamnetin is a quercetin derivative found in Coriandrum sativum, inhibits secretory phospholipase A2, with antioxidant and anti-inflammatory activity .
|
-
- HY-168765
-
LSN433771
|
Phospholipase
|
Cardiovascular Disease
|
LY433771 (LSN433771) (Compound 8) is a type X secretory phospholipase A2 (sPLA2) inhibitor with an IC50 value of 3 nM, which can be used in the study of cardiovascular diseases .
|
-
- HY-B0428
-
Ozagrel
1 Publications Verification
OKY-046
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM .
|
-
- HY-107393
-
|
Phospholipase
|
Inflammation/Immunology
|
LY-311727 is a potent secretory non-pancreatic phospholipase A2 (sPLA2) inhibitor (IC50 <1 μM for group IIA sPLA2). sPLA2 is an important proinflammatory enzyme .
|
-
- HY-136466
-
A2ti-2
1 Publications Verification
|
Annexin A
Virus Protease
HPV
|
Infection
|
A2ti-2 is a selective and low-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 230 μM . A2ti-2 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-2 prevents human papillomavirus type 16 (HPV16) infection .
|
-
- HY-136465
-
A2ti-1
2 Publications Verification
|
Annexin A
Virus Protease
HPV
|
Infection
|
A2ti-1 is a selective and high-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 24 μM . A2ti-1 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-1 prevents human papillomavirus type 16 (HPV16) infection .
|
-
- HY-142669
-
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
Lp-PLA2-IN-4 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-4 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 38) .
|
-
- HY-142670
-
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
Lp-PLA2-IN-5 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-5 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 32) .
|
-
- HY-N12555
-
|
Others
|
Others
|
6,6′-Didemethyl-7-methyl dragonbloodin A2 is isolated from the dragon’s blood of Daemonorops draco fruits and is a osteoclastogenesis inhibitor with IC50 value of 36.8 μM[1].
|
-
- HY-114721
-
MEDI-564
|
RSV
|
Infection
|
BTA-9881 (MEDI-564) is a RSV inhibitor, with an EC50: 48 nM, 59 nM and 160 nM for RSV A2, RSV Long, and RSV B1. BTA-9881 has favorable pharmacokinetics property .
|
-
- HY-B0128
-
-
- HY-102004
-
SB 659032
|
Phospholipase
|
Neurological Disease
Inflammation/Immunology
|
Rilapladib (SB 659032) is a selective Lp-PLA2 (lipoprotein-associated phospholipase A2) inhibitor with an IC50 of 230 pM . Rilapladib (SB 659032) is also a PAFR (Platelet Activating Factor Receptor) antagonist .
|
-
- HY-133148
-
|
Phospholipase
|
Inflammation/Immunology
|
Lp-PLA2-IN-2 is a potent and selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 0f 120 nM for recombinant human Lp-PLA2 .
|
-
- HY-17485
-
EB-382
|
Phospholipase
COX
|
Inflammation/Immunology
|
Alminoprofen (EB-382) is a nonsteroidal anti-inflammatory agent (NSAID) of the phenylpropionic acid class. Alminoprofen possesses a dual anti-inflammatory action, by inhibiting both secretory phospholipase A2 (sPLA2) and COX-2 .
|
-
- HY-106080A
-
U-63557A
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .
|
-
- HY-118725
-
|
Phospholipase
|
Inflammation/Immunology
|
Luffariellolide is an inhibitor of human synovial fluid phospholipase A2 (HSF-PLA2) (IC50=5 μM). Luffariellolide effectively inhibits phorbol ester (PMA)-induced ear edema (ED50=50 μg/ear) .
|
-
- HY-19757
-
-
- HY-133149
-
|
Phospholipase
|
Cardiovascular Disease
|
Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2) .
|
-
- HY-116301
-
|
Phospholipase
|
Inflammation/Immunology
|
CAY10502 is a potent, calcium-dependent cytosolic phospholipase A2 α (cPLA2α) inhibitor with an IC50 of 4.3 nM for isolated enzyme. CAY10502 can be used in the research of retinopathy and inflammatory diseases .
|
-
- HY-145653
-
-
- HY-142779
-
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-11 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2014114249A1, compound E145) .
|
-
- HY-101579
-
|
COX
Lipoxygenase
Phospholipase
|
Inflammation/Immunology
|
LY 178002 is a potent inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2, with IC50 of 0.6 μM for 5-lipoxygenase, inhibits cellular production of LTB4 by human polymorphonuclear leukocytes, and shows relatively weak inhibition on cyclooxygenase.
|
-
- HY-106080
-
U-63557A free acid
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate is being developed as an antiplatelet agent .
|
-
- HY-105120A
-
GR 32191 hydrochloride
|
Prostaglandin Receptor
|
Others
|
Vapiprost hydrochloride (GR 32191 hydrochloride) is a thromboxane A2 receptor antagonist. Vapiprost hydrochloride (GR 32191 hydrochloride) inhibits the aggregation and ATP release stimulated with U-46619, collagen or arachidonic acid (AA) at an IC50 of less than 2.1×10 -8 M .
|
-
- HY-116018
-
|
Phospholipase
|
Neurological Disease
Inflammation/Immunology
Cancer
|
FKGK11 is a potent and selective inhibitor of GVIA iPLA2 (Group VIA calcium-independent phospholipase A2). FKGK11 can be used for the research of ovarian cancer and neurological disorders such as peripheral nerve injury and multiple sclerosis .
|
-
- HY-101257A
-
|
CDK
|
Cancer
|
CDK7-IN-1, an analog of YKL-5-124, is a cyclin-dependent kinase 7 (cdk7) inhibitor, with an IC50 of less than 100 nM, extracted from patent WO 2016105528 A2, Compound 215 .
|
-
- HY-119375
-
|
Bacterial
|
Infection
|
Syncytial Virus Inhibitor-1 is a potent, orally bioavailable respiratory syncytial virus (RSV) fusion inhibitor with EC50s of 0.002 μM, 0.004 μM, and 0.002 μM for RSV Long, RSV A2, and RSV B strains, respectively .
|
-
- HY-B0745S
-
-
- HY-B1735
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases .
|
-
- HY-N1450R
-
|
Phospholipase
|
Cancer
|
Aristolochic acid C (Standard) is the analytical standard of Aristolochic acid C. This product is intended for research and analytical applications. Aristolochic acid C is a derivative of Aristolochic acid. Aristolochic acid is a phospholipase A2 (PLA2) inhibitor, which disrupts cortical microtubule arrays and root growth in Arabidopsis .
|
-
- HY-18763S
-
Ibustrin-d5
|
Isotope-Labeled Compounds
COX
|
Cardiovascular Disease
|
Indobufen-d5 is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes[1].
|
-
- HY-B0428BR
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Ozagrel (hydrochloride) (Standard) is the analytical standard of Ozagrel (hydrochloride). This product is intended for research and analytical applications. Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC50 of 53.12 μM .
|
-
- HY-142778
-
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-10 has the potential for the research of neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis (extracted from patent WO2022001881A1, compound 4) .
|
-
- HY-18763R
-
|
COX
|
Cardiovascular Disease
|
Indobufen (Standard) is the analytical standard of Indobufen. This product is intended for research and analytical applications. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .
|
-
- HY-105120
-
GR 32191
|
Prostaglandin Receptor
|
Others
|
Vapiprost (GR 32191) is a thromboxane A2 receptor (TXA2 Receptor) antagonist. Vapiprost hydrochloride (GR 32191 hydrochloride) inhibits the aggregation and ATP release stimulated with U-46619, collagen or arachidonic acid (AA) at an IC50 of less than 2.1×10 -8 M .
|
-
- HY-N0604R
-
Prosapogenin A2 (Standard); Sanchinoside B2 (Standard); Sanchinoside Rh1 (Standard)
|
Interleukin Related
PPAR
TNF Receptor
Endogenous Metabolite
|
Inflammation/Immunology
|
Ginsenoside Rh1 (Standard) is the analytical standard of Ginsenoside Rh1. This product is intended for research and analytical applications. Ginsenoside Rh1 (Prosapogenin A2) inhibits the expression of PPAR-γ, TNF-α, IL-6, and IL-1β.
|
-
- HY-B0428D
-
(E/Z)-OKY-046 sodium
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
(E/Z)-Ozagrel (sodium) [(E/Z)-OKY-046 (sodium)] is an EZ configuration mixture of Ozagrel (sodium) (HY-B0428A). Ozagrel (sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel (sodium) is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM .
|
-
- HY-100287
-
|
Prostaglandin Receptor
Phospholipase
|
Endocrinology
|
2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide is a compound that inhibits stress-induced ulcer and low toxicity, and can maintain the content of phospholipase A2 and prostaglandin E2 in ulcerated rats induced by water immersed restrained stress.
|
-
- HY-11059
-
|
Phospholipase
|
Inflammation/Immunology
|
sPLA2 inhibitor 1, a D-tyrosine derivative, is an orally active, potent secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 29 nM for human nonpancreatic secretory PLA2 isoform IIa (hnpsPLA2-IIa). sPLA2 inhibitor 1 has anti-inflammatory activity .
|
-
- HY-19151
-
IS-741
|
Integrin
Phospholipase
|
Inflammation/Immunology
|
Fuzapladib (IS-741), an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site .
|
-
- HY-19151A
-
IS-741 sodium
|
Integrin
Phospholipase
|
Inflammation/Immunology
|
Fuzapladib (IS-741) sodium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib sodium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib sodium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site .
|
-
- HY-N2330
-
|
Lipase
|
Metabolic Disease
|
Lipstatin is a pancreatic lipase inhibitor (IC50=0.14 μM), whose structure is closely related to the known inhibitor, Esterastin. Lipstatin inhibits the absorption of triglycerides without affecting the absorption of oleic acid. Lipstatin has no inhibitory effects on other pancreatic enzymes, such as phospholipase A2 and trypsin (<200 μM) .
|
-
- HY-19151B
-
IS-741 potassium
|
Integrin
Phospholipase
|
Inflammation/Immunology
|
Fuzapladib (IS-741) potassium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib potassium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib potassium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site .
|
-
- HY-19151C
-
IS-741 calcium
|
Integrin
Phospholipase
|
Inflammation/Immunology
|
Fuzapladib calcium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib calcium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib calcium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site .
|
-
- HY-160664
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
TP receptor antagonist-2 (example 7n) is a thromboxane A2 receptor (TP receptor) antagonist, with IC50 values of 5.64 and 5.27 μM for TPα and TPβ, respectively. TP receptor antagonist-2 inhibits platelet aggregation .
|
-
- HY-170507
-
|
CDK
|
Cancer
|
CDK-IN-16 (Compound 5g) is a CDK2/cyclin A2 inhibitor with an IC50 of 1.67 μM. CDK-IN-16 exhibits anticancer activity. The IC50 of CDK-IN-16 against the AGS cell line is 3.5 μM .
|
-
- HY-107411
-
(6E)-Bromoenol lactone
|
Phospholipase
|
Inflammation/Immunology
|
Bromoenol lactone ((6E)-Bromoenol lactone) is a suicide-based irreversible, selective, potent inhibitor of calcium-independent phospholipase A2 (iPLA2β) with an IC50 value of approximately 7 μM, which inhibits antigen-stimulated mast cell exocytosis without blocking Ca 2+ influx .
|
-
- HY-117842
-
|
Histamine Receptor
|
Inflammation/Immunology
|
KY 234 is an orally effective inhibitor that targets thromboxane A2 production, with an IC50 of 5 μM. KY 234 significantly inhibits leukotriene D4 (LTD4), histamine, and antigen-induced bronchoconstriction in guinea pigs, with IC50 values of 6.0 mg/kg, 2.5 mg/kg, and 6.3 mg/kg, respectively .
|
-
- HY-169313
-
|
RSV
|
Infection
|
HRSV/HMPV-IN-1 (compound 3) is a HRSV/HMPV inhibitor with the EC50 values of < 0.2 μM and < 0.5 μM for human RSV-A and human MPV A2 TN/94-49, respectively. HRSV/HMPV-IN-1 can be used for study of bronchiolitis and pneumonia .
|
-
- HY-118628
-
N-(p-Amylcinnamoyl) anthranilic acid; ACA
|
Phospholipase
TRP Channel
|
Cardiovascular Disease
|
(E/Z)-BML264 (N-(p-amylcinnamoyl) Anthranilic Acid) is a broad spectrum Phospholipase A2 (PLA2) inhibitor and TRP channel blocker . (E/Z)-BML264 (N-(p-amylcinnamoyl) Anthranilic Acid) is also an effective reversible inhibitor of calcium-activated chloride channels, has potential to treat arrhythmia .
|
-
- HY-112605
-
|
Phospholipase
|
Cardiovascular Disease
|
sPLA2-X Inhibitor 31 is a selective secreted phospholipase A2 type X (sPLA2-X) inhibitor with IC50s of 26 nM, 310 nM, and 2230 nM for sPLA2-X, sPLA2-IIa, and sPLA2-V, respectively .
|
-
- HY-14654B
-
Acetylsalicylic acid DL-lysine; ASA DL-lysine
|
COX
NF-κB
p38 MAPK
|
Cardiovascular Disease
Others
Inflammation/Immunology
|
Aspirin DL-lysine (ASA DL-lysine) is a lysine-containing aspirin derivative. Aspirin DL-lysine inhibits cyclooxygenase (COX) in platelets, blocks the synthesis of thromboxane A2 (TXA2), and thus inhibits platelet aggregation and activation. Aspirin DL-lysine can be used to study thrombin generation in patients with unstable angina pectoris .
|
-
- HY-17485R
-
|
Phospholipase
COX
|
Inflammation/Immunology
|
Alminoprofen (Standard) is the analytical standard of Alminoprofen. This product is intended for research and analytical applications. Alminoprofen (EB-382) is a nonsteroidal anti-inflammatory agent (NSAID) of the phenylpropionic acid class. Alminoprofen possesses a dual anti-inflammatory action, by inhibiting both secretory phospholipase A2 (sPLA2) and COX-2 .
|
-
- HY-B0128R
-
|
Adenosine Receptor
Phosphodiesterase (PDE)
|
Cardiovascular Disease
Inflammation/Immunology
|
Diphylline (Standard) is the analytical standard of Diphylline. This product is intended for research and analytical applications. Diphylline (Diprophylline) is a potent A1/A2 adenosine receptor antagonist and cyclic nucleotide phosphodiesterase inhibitor. Diphylline, a xanthine derivative, is a bronchodilator and vasodilator agent and has the potential for chronic bronchitis and emphysema .
|
-
- HY-12291
-
HMSL 10017-101-1
|
Raf
|
Cancer
|
HG6-64-1 is a potent and selective B-Raf inhibitor extracted from patent WO 2011090738 A2, example 9 (XI-1); has a IC50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells.
|
-
- HY-101015
-
|
Phospholipase
Apoptosis
|
Inflammation/Immunology
|
(2E)-OBAA is a potent phospholipase A2 (PLA2) inhibitor, with an IC50 of 70 nM. (2E)-OBAA induces apoptosis of HUVEC cells. (2E)-OBAA blocks Melittin-induced Ca 2+ influx in Trypanosoma brucei, with an IC50 of 0.4 μM .
|
-
- HY-B0774
-
-
- HY-108561
-
|
Prostaglandin Receptor
|
Others
|
L-670596 is an orally active and selective thrombsxane A2 receptor/prostaglandin receptor antagonist. L-670596 inhibits arachidonic acid (HY-109590) and U-44069 induced bronchoconstriction in the guinea pig. L-670596 also inhibits the aggregation of human platelet rich plasma induced by U-44069 .
|
-
- HY-125986
-
|
Phospholipase
|
Neurological Disease
|
GK187 is a potent and selective Group VIA calcium-independent phospholipase A2 (GVIA iPLA2) inhibitor with an XI(50) value of 0.0001. GK187 can be used for researching various neurological disorders .
[The XI(50) is the mole fraction of the inhibitor in the total substrate interface required to inhibit the enzyme by 50%.]
|
-
- HY-123400A
-
iso-DTTX30; iso-DT-TX 30 SE
|
Others
|
Cardiovascular Disease
|
Iso-Samixogrel (iso-DTTX30) is a combined thromboxane A2 receptor blocker and thromboxane synthetase inhibitor that exhibits potent antithrombotic activity. Iso-Samixogrel effectively eliminates recurrent arterial thrombus formation and inhibits collagen-induced platelet aggregation ex vivo. Iso-Samixogrel also prolongs sublingual bleeding time, demonstrating its biological efficacy in managing thrombosis.
|
-
- HY-105218
-
BMS-180291
|
Prostaglandin Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
Ifetroban (BMS-180291) is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .
|
-
- HY-115403
-
FKGK18
1 Publications Verification
|
Phospholipase
Apoptosis
|
Metabolic Disease
|
FKGK18 is a selective group VIA calcium-independent phospholipase A2 (GVIA iPLA2) inhibitor. FKGK18 is a fluoroketone (FK)-based compound with IC50s of 50 nM and 3 μM for iPLA2β and iPLA2γ. FKGK18 can be used for the research of beta-cell apoptosis and diabetes .
|
-
- HY-105218A
-
BMS-180291 sodium
|
Prostaglandin Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .
|
-
- HY-137227
-
15(R)-Pinanethromboxane A2
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
15(R)-PTA2 (15(R)-Pinanethromboxane A2) is an antithrombotic agent that inhibits platelet aggregation. 15(R)-PTA2 inhibits stable prostaglandin endoperoxide analog-induced constriction of feline coronary arteries and stabilizes hepatic lysosomes. 15(R)-PTA2 also inhibits thromboxane synthase but has no effect on prostacyclin synthase .
|
-
- HY-13402
-
LY315920
|
Phospholipase
|
Inflammation/Immunology
|
Varespladib (LY315920) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively .
|
-
- HY-13402A
-
LY315920 sodium
|
Phospholipase
|
Inflammation/Immunology
|
Varespladib sodium (LY315920 sodium) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib sodium exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively .
|
-
- HY-123245
-
|
TRP Channel
Phospholipase
ERK
Akt
|
Inflammation/Immunology
Cancer
|
Scalaradial is an inhibitor for bee venom phospholipase A2 (PLA2) and transient receptor potential melastatin 2 (TRPM2) ion channels, with IC50 of 0.07 and 0.21 μM. Scalaradial regulates the phosphorylation of ERK, by inhibiting secretory PLA2 and Akt. Scalaradial inhibits the PMA (HY-18739)-induced release of Arachidonic acid (HY-109590) in the mouse peritoneal macrophage .
|
-
- HY-114873
-
LY25684
|
Phospholipase
COX
Lipoxygenase
Leukotriene Receptor
|
Inflammation/Immunology
|
LY256548 (LY25648) is an orally available anti-ischemic and anti-inflammatory compound with central nervous system activity. LY256548 is an inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and COX, and inhibits A23187 (HY-N6687)-stimulated leukotriene B4 production. LY256548 inhibits bone damage and paw swelling in the rat Freund's complete adjuvant-induced arthritis (FCA) model .
|
-
- HY-127110
-
|
Phospholipase
|
Others
Neurological Disease
Inflammation/Immunology
|
AK106-001616 is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2) (IC50=3.8 nmol/L). AK106-001616 is able to reduce the production of prostaglandins (PG) E2 and leukotrienes (LT) B4 by stimulated cells. AK106-001616 can be used in the study of inflammatory diseases, neuropathic pain and pulmonary fibrosis .
|
-
- HY-B0774R
-
-
- HY-N7327
-
|
Phospholipase
|
Inflammation/Immunology
|
Ochnaflavone is an inhibitor of IIA-type secretory phospholipase A2 (sPLA2-IIA) with an IC50 of 3.45 µM. Ochnaflavone exhibits significant anti-inflammatory and liver-protective effects, capable of inhibiting the degradation of phosphatidylethanolamine (PE) and lipid peroxidation induced by carbon tetrachloride (CCl4) in rat liver, with an IC50 of 7.16 µM for lipid peroxidation. Ochnaflavone can be used in research on liver damage and inflammatory diseases .
|
-
- HY-126849
-
-
- HY-23909
-
DEDA
|
Phospholipase
|
Inflammation/Immunology
|
7,7-Dimethyl-(5Z,8Z)-eicosadienoic acid (DEDA), a phospholipase inhibitor, is a non-metabolizable analog of arachidonic or eicosadienoic acid. 7,7-Dimethyl-(5Z,8Z)-eicosadienoic acid (DEDA) inhibits P388D1 cell phospholipase A2 (PLA2) (IC50 = 16 µM) and snake venom PLA2 (IC50 = 14 µM) .
|
-
- HY-146108
-
|
RSV
|
Infection
|
RSV-IN-5 (Compound 4) is a potent dual inhibitor of wild-type and mutant respiratory syncytial virus (RSV) fusion proteins. RSV-IN-5 exhibits potent anti-RSV activities against not only wild-type A2 F protein (EC50=2.0 nM), but also D486N-mutant F protein (EC50=8.1 nM) .
|
-
- HY-138990
-
|
Phospholipase
Apoptosis
|
Inflammation/Immunology
|
GK563 is a selective Ca 2+-independent phospholipase A2 (GVIA iPLA2) inhibitor with an IC50 value of 1 nM. GK563 is 22000 times more active against GVIA iPLA2 than GIVA cPLA2. GK563 reduces β-cell apoptosis induced by proinflammatory cytokines, raising the possibility that it can be beneficial in countering autoimmune diseases, such as type 1 diabetes .
|
-
- HY-P4032
-
|
HCV
|
Inflammation/Immunology
|
HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .
|
-
- HY-134082A
-
|
Phospholipase
|
Inflammation/Immunology
|
(Z)-Oleyloxyethyl phosphorylcholine ((Z)-OPC) is an isomer of Oleyloxyethyl phosphorylcholine (OPC). Oleyloxyethyl phosphorylcholine is an inhibitor of secreted Phospholipase A2 (sPLA2), which is involved in the biosynthesis of proinflammatory lipid media. Oleyloxyethyl phosphorylcholine can be used to study inflammatory diseases. Oleyloxyethyl phosphorylcholine also modified the red blood membrane and was used to bind the oxygen-carrying liquid perfluorocarbons as an antivenom agent to reduce toxin-induced hemolysis .
|
-
- HY-108611
-
AACOCF3
3 Publications Verification
Arachidonyl trifluoromethyl ketone
|
Phospholipase
|
Cardiovascular Disease
|
AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeant trifluoromethyl ketone analog of arachidonic acid. AACOCF3 is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A2 (cPLA2). AACOCF3 blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. AACOCF3 inhibits glucose-induced insulin secretion from isolated rat islets. AACOCF3 has the potential for the research of cardiovascular disease .
|
-
- HY-120050
-
|
Phospholipase
|
Inflammation/Immunology
|
GK470 (compound 28) is an inhibitor of group IVA cytosolic phospholipase A2 (GIVA cPLA2) with an IC50 of 300 nM in vesicle assays. GK470 has anti-inflammatory activity, inhibiting the release of arachidonic acid in SW982 fibroblast-like synoviocytes with an IC50 value of 0.6 μM. GK470 exhibits comparable anti-inflammatory effects to Methotrexate (HY-14519) in a preventive collagen-induced arthritis model and significantly reduces plasma PGE2 levels .
|
-
- HY-120078
-
|
Phospholipase
|
|
AZD2716 is a selective sPLA2 (secretory phospholipase A2) inhibitor. AZD2716 significantly reduces the production of pro-inflammatory lipids by inhibiting sPLA2-IIa (IC50 = 10 nM), sPLA2-V (IC50 = 40 nM), and sPLA2-X (IC50 = 400 nM), thereby decreasing macrophage activation and foam cell formation. AZD2716 is promising for studying mechanisms related to atherosclerosis and inflammatory diseases associated with sPLA2 .
|
-
- HY-W127380
-
|
Biochemical Assay Reagents
|
Others
|
Arachidonoyl Thio-PC is a substrate of many phospholipase A2 (PLA2), including sPLA2, cPLA2 and iPLA2. Cleavage of sn-2 fatty acids by PLA2 results in the production of free thiols, which react with chromogenic reagents such as DTNB (Ellman's reagent) and DTP, allowing quantification of PLA2 activity. Isozyme-specific cPLA2 activity can be measured by depleting or inhibiting sPLA2 and iPLA2 activity in the assay.
|
-
- HY-134914
-
|
Antibiotic
Parasite
|
Infection
|
Fosmidomycin is an orally active antibiotic, which exhibits antimalarial activity through inhibition of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DOXP reductoisomerase). Fosmidomycin inhibits P. falciparum strains 3D7, HB3, Dd2 and A2, with IC50s of 150, 71, 170 and 150 ng/mL, respectively. Fosmidomycin exhibits synergistic effect with Clindamycin (HY-B1455), and ameliorates malaria in mouse model .
|
-
- HY-114564
-
E5510
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Satigrel (E5510) is a potent inhibitor of platelet aggregation. Satigrel inhibits collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC50: 0.081 μM) and PGHS2 (IC50: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC50: 15.7 μM, 39.8 μM and 62.4 μM, respectively) .
|
-
- HY-161515
-
|
NAMPT
Epigenetic Reader Domain
|
Cancer
|
BRD4/NAMPT-IN-1 (Compound A2) shows strong inhibitory effects on NAMPT and BRD4 (IC50=35 nM (NAMPT) and 58 nM (BRD4)). BRD4/NAMPT-IN-1 inhibits the growth and migration of hepatocellular carcinoma cells and promotes apoptosis. BRD4/NAMPT-IN-1 also shows potent anticancer effects in HCCLM3 xenograft mouse model, with no obvious toxic effects .
|
-
- HY-135564A
-
|
Phosphatase
Phospholipase
HIV Protease
ERK
Autophagy
|
Infection
Cancer
|
RK-682 is the inhibitor for protein tyrosine phosphatase (PTPase), heparanase, phospholipase A2 and HIV-1 protease. RK-682 inhibits the dephosphorylation of CD45 (IC50 is 54 μM) and VHR (IC50 is 2.0 μM), and thereby inhibits the ERK signaling pathway. RK-682 inhibits the cell viability of cancer cell MGH-U3, T24 and UROtsa with IC50s of 78.2, 43.2 and 145 nM, respectively, arrests the cell cycle at G1/S phase, inhibits the cell migration and autophagy in MGH-U3 and T24 .
|
-
- HY-153221
-
|
CDK
|
Cancer
|
QR-6401 is an orally active and selective macrocyclic CDK2 inhibitor with IC50 values of 0.37, 10, 22, 34 and 45 nM for CDK2/E1, CDK9/T1, CDK1/A2, CDK6/D3 and CDK4/D1, respectively. QR-6401 has potent antitumor activity in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer .
|
-
- HY-D0837
-
Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene
|
Ser/Thr Protease
Thrombopoietin Receptor
|
Neurological Disease
Inflammation/Immunology
|
Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
|
-
- HY-133233
-
1-Palmitylthio-2-palmitoylamido-1,2-dideoxy-sn-glycero-3-phosphorylcholine
|
Endogenous Metabolite
Phospholipase
|
Metabolic Disease
|
Thioetheramide-PC (1-Palmitylthio-2-palmitoylamido-1,2-dideoxy-sn-glycero-3-phosphorylcholine) is a structurally modified phospholipid that acts as a competitive, reversible inhibitor of secretory phospholipase A2 (sPLA2). Thioetheramide-PC has an IC50 value of 2 μM at a substrate concentration of 0.5 mM. In addition to binding to the catalytic site of sPLA2, Thioetheramide-PC also binds to the activation site of the enzyme. Thioetheramide-PC binds more tightly to the activation site than to the catalytic site. As a result of this dual interaction, at low concentrations, Thioetheramide-PC may activate phospholipase activity rather than inhibit it.
|
-
- HY-156041
-
Lyso-PE (egg); LPE (egg); L-α-lysophosphatidylethanolamine
|
Endogenous Metabolite
|
Metabolic Disease
|
Lysophosphatidylethanolamine (LPE) is a naturally-occurring lysophospholipid that can be generated via deacylation of phosphatidylethanolamine by phospholipase A2 (PLA2). It increases the phosphorylation of ERK1/2 in PC12 cells, an effect that can be blocked by the MEK inhibitors U-0126 (HY-12031A) and PD 98059 (HY-12028) and the EGFR inhibitor AG-1478 (HY-13524).1 LPE also increases neurite outgrowth and expression of neurofilament M in PC12 cells. LPE inhibits the activity of phospholipase D (PLD) partially purified from cabbage.3 This product contains lysophosphatidylethanolamine molecular species with variable fatty acyl chain lengths at the sn-1 position and a hydroxy group at the sn-2 position.
|
-
- HY-18540
-
|
DAGL
MAGL
|
Metabolic Disease
Inflammation/Immunology
|
KT109 is a potent and an isoform-selective inhibitor of diacylglycerol lipase-β (DAGLβ) with an IC50 of 42 nM. KT109 has ~60-fold selectivity for DAGLβ over DAGLα. KT109 shows inhibitory activity against PLA2G7 (IC50=1 µM). KT109 shows negligible activity against FAAH, MGLL, ABHD11, and cytosolic phospholipase A2 (cPLA2 or PLA2G4A). KT109 perturbs a lipid network involved in macrophage inflammatory responses and lowers 2-arachidonoylglycerol (2-AG), arachidonic acid and eicosanoids in mouse peritoneal macrophages .
|
-
- HY-135564
-
|
Phosphatase
Phospholipase
HIV Protease
ERK
Autophagy
|
Infection
Cancer
|
RK-682 hemicalcium is the hemicalcium salt form of RK-682 (HY-135564A). RK-682 hemicalcium is the inhibitor for protein tyrosine phosphatase (PTPase), heparanase, phospholipase A2 and HIV-1 protease. RK-682 hemicalcium inhibits the dephosphorylation of CD45 (IC50 is 54 μM) and VHR (IC50 is 2.0 μM), and thereby inhibits the ERK signaling pathway. RK-682 hemicalcium inhibits the cell viability of cancer cell MGH-U3, T24 and UROtsa with IC50s of 78.2, 43.2 and 145 nM, respectively, arrests the cell cycle at G1/S phase, inhibits the cell migration and autophagy in MGH-U3 and T24 [2] .
|
-
- HY-D0837R
-
|
Ser/Thr Protease
Thrombopoietin Receptor
|
Neurological Disease
Inflammation/Immunology
|
Imidazole (Standard) is the analytical standard of Imidazole. This product is intended for research and analytical applications. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
|
-
- HY-W699983
-
Glyoxaline-15N2; 1,3-Diaza-2,4-cyclopentadiene-15N2
|
Isotope-Labeled Compounds
Thrombopoietin Receptor
Ser/Thr Protease
|
Neurological Disease
Inflammation/Immunology
|
Imidazole- 15N2 (Glyoxaline- 15N2) is 15N labeled Imidazole. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
|
-
- HY-161826
-
|
β-catenin
HSP
CDK
c-Myc
|
Cancer
|
Antitumor agent-174 (Compound 10) directly engages the N-terminal site of Hsp90 and promotes the degradation of β-catenin, thereby suppressing the Wnt/β-catenin signaling. Antitumor agent-174 effectively inhibits proliferation, induce S and G2/M phases arrest and block the clonogenic ability in CRC cells. Antitumor agent-174 down-regulates CDK1, Cyclin D1, c-Myc, Cyclin B1, and Cyclin A2, and upregulaties P21 proteins. Antitumor agent-174 has significant anti-tumor efficacy against colorectal cancer (CRC) with excellent pharmacokinetics and low toxicity .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-W100403
-
Choline p-toluenesulfonate
|
Enzyme Substrates
|
Choline tosylate is a nucleophilic compound that inhibits phospholipase A2 and phospholipase C. Choline tosylate inhibits tumor growth in mice by inhibiting the formation of diacylglycerol (DAG) .
|
-
- HY-D0837
-
Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene
|
Cell Assay Reagents
|
Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
|
-
- HY-W127380
-
|
Enzyme Substrates
|
Arachidonoyl Thio-PC is a substrate of many phospholipase A2 (PLA2), including sPLA2, cPLA2 and iPLA2. Cleavage of sn-2 fatty acids by PLA2 results in the production of free thiols, which react with chromogenic reagents such as DTNB (Ellman's reagent) and DTP, allowing quantification of PLA2 activity. Isozyme-specific cPLA2 activity can be measured by depleting or inhibiting sPLA2 and iPLA2 activity in the assay.
|
-
- HY-D0837R
-
|
Cell Assay Reagents
|
Imidazole (Standard) is the analytical standard of Imidazole. This product is intended for research and analytical applications. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3884
-
|
Bacterial
Antibiotic
|
Infection
|
Arylomycin A2, an antibiotic (Antibiotic), is a lipopeptide type I signal peptidase (SPase I) inhibitor. Arylomycin A2 has antibacterial effects .
|
-
- HY-P2333
-
LCKLSL
5 Publications Verification
|
Peptides
|
Cardiovascular Disease
|
LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL also inhibits the generation of plasmin and has anti-angiogenic roles .
|
-
- HY-P2333A
-
|
Peptides
|
Cardiovascular Disease
|
LCKLSL hydrochloride is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL hydrochloride potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL hydrochloride also inhibits the generation of plasmin and has anti-angiogenic roles .
|
-
- HY-P4032
-
|
HCV
|
Inflammation/Immunology
|
HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .
|
-
- HY-P10053
-
|
Phospholipase
|
Metabolic Disease
|
sPLA2-IIA Inhibitor is a cyclic pentapeptide analog of FLSYK (cyclic 2-Nal-Leu-Ser-2-Nal-Arg (c2)), that binds to hGIIA (human IIA phospholipase A2) and inhibits its hydrolytic ability. sPLA2 is a member of the esterase superfamily that catalyzes the hydrolysis of the ester bond at the sn-2 position of glycerophospholipids, releasing free fatty acids such as arachidonic acid and lysophospholipids .
|
-
- HY-P10785
-
|
Bacterial
Antibiotic
|
Infection
|
Iturin A-2 is a cyclic lipopeptide discovered in B. subtilis and exhibits inhibitory activity against the plant pathogenic fungus P. expansum (MIC = 8 µg/disk). Iturin A-2 is cytotoxic to MCF-7 and BT474 breast cancer cells, as well as HeLa cervical cancer cells, with IC50 values of 66.81, 95.04, and 77.5 µg/mL, respectively. In greenhouse studies, Iturin A-2 at concentrations of 100 and 300 mg/kg Iturin A-2 reduces the lesion area of southern corn leaf blight caused by B. maydis, and in field studies, concentrations of 300 and 500 mg/kg Iturin A-2 reduce the incidence of the disease. Iturin A-2 (12.5 µg/mL) inhibits cell division, but not nuclear division, in isolated fertilized starfish eggs .
|
-
- HY-113560
-
-
- HY-P10447
-
Fengycin IX; SNA-60-367-3
|
Phospholipase
|
Inflammation/Immunology
|
Plipastatin A1 is a lipopeptide with enzyme inhibitory and immunosuppressive activities. Plipastatin A1 is found in Bacillus cereus and inhibits phospholipase A2 (PLA2), PLC, and PLD .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0745S
-
|
Ramatroban-d4 is deuterium labeled Ramatroban. Ramatroban is a selective thromboxane A2 (TxA2, IC50=14 nM) antagonist, which also antagonizes CRTH2 (IC50=113 nM) by inhibiting PGD2 binding.
|
-
-
- HY-18763S
-
|
Indobufen-d5 is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes[1].
|
-
-
- HY-W699983
-
|
Imidazole- 15N2 (Glyoxaline- 15N2) is 15N labeled Imidazole. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: